在初级慢性非细菌性下骨髓炎中TNF-α阻断
Jeanne de La Rochefoucauld1, Raphaël Lhote1, Mourad-Azzedine Benassarou2
1Department of Internal Medicine, AP-HP, Pitié-Salpêtrière Hospital, Institut E3M, French National Reference Center for Rare Systemic Diseases, Sorbonne Université, Paris, France.
Rheumatology (Oxford, England)
|July 23, 2024
概括
瘤坏死因子-α (TNF-α) 阻断为下的慢性非细菌性骨髓炎 (CNOM) 提供了有效和安全的治疗方法. 这种疗法在大多数患者中实现了快速缓解,即使是那些患有长期耐火性疾病的患者.
科学领域:
- 自发炎性疾病是自发炎性疾病.
- 骨髓炎是一种骨质炎.
- 免疫学 免疫学 免疫学
背景情况:
- 初级慢性非细菌下骨髓炎 (CNOM) 是一种罕见的自身炎症性疾病.
- CNOM与SAPHO综合征和CRMO有相似之处,它们对TNF-α阻断有反应.
- 之前的CNOM治疗产生了令人失望的结果,缺乏TNF-α阻断的临床数据.
研究的目的:
- 追溯评估抗TNF-α治疗在不耐药的CNOM患者中的疗效和安全性.
- 提供支持TNF-α阻断作为CNOM治疗选择的临床数据.
主要方法:
- 对15名耐火性CNOM和高疾病负担患者的回顾性分析.
- 由于治疗失败和治疗相关疾病的有效性,针对10名患者进行了抗TNF-α治疗.
- 记录了抗TNF-α治疗的详细结果.
主要成果:
- 抗TNF-α治疗导致大多数CNOM患者的快速和持续缓解.
- 在TNF-α阻断治疗期间没有报告任何严重不良事件.
- 一些患者实现了缓解,并停止了治疗而没有复发,尽管多年来耐药性疾病.
- 男性的性别与不太有利的结果有关.
结论:
- 阻断TNF-α是CNOM的有效和安全的治疗选择.
- 这项研究提供了第一个支持在CNOM中使用TNF-α阻断的临床数据.
- 进一步的研究可能会探索影响治疗结果的因素,例如性别.
相关概念视频
NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...


